| 控制的法人 | | --- | | 收 | | 款 | | | | | | | | | 性往来 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 有限公司 | | | | | | | | | | | | | | 非经营 | | | | | | | | | | | | | | 关联自然人 | 无 | | | | | | | | | | | | | 性往来 | | | | | | | | | | | | | | 其他关联方及 | | | | | | | | | | | | 非 | | 经营 | | | | | | | | | | | | | | 无 | | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 性 | | 往来 | | | | | | | | | | | | | | 总计 | / | / | / | 929,918,531.07 | 169,099,187.45 | - | 297,511,725.72 | 80 ...

关于对药源药物化学（上海）有限公司业绩承诺 期届满资产减值测试专项审核报告 上海皓元医药股份有限公司 容诚专字2025200Z0331 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 关于对药源药物化学（上海）有限公司业绩承诺期届满 序号 内 容 页码 上海皓元医药股份有限公司关于对药源药物化学（上 海）有限公司业绩承诺期届满资产减值测试报告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 TEL:010-6600 1391 FAX:010-6600 1392 上海皓元医药股份有限公司 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 资产减值测试专项审核报告 容诚专字2025200Z0331 号 上海皓元医药股份有限公司全体股东： 我们接受委托，审核了上海皓元医药股份有限公司（以下简称皓元医药）管理 层编制的《上海皓元医药股份有限公司关于对药源药物化学（上海）有限公司业绩 承诺期届满资产减值测试报告》（以下简称减值测试报告）。 一、管理层的责任 按照中国证券监督管理委员会《上市公司重大资产重组管理办法》（中国 ...

募集资金存放与实际使用情况鉴证报告 上海皓元医药股份有限公司 容诚专字2025200Z0250号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 序号 内 容 页码 募集资金存放与实际使用情况鉴证报告 容诚专字2025200Z0250号 上海皓元医药股份有限公司全体股东： 我们审核了后附的上海皓元医药股份有限公司（以下简称皓元医药）董事会编 制的《2024 年度募集资金存放与使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供皓元医药年度报告披露之目的使用，不得用作任何其他目的。 我们同意将本鉴证报告作为皓元医药年度报告必备的文件，随其他文件一起报送 并对外披露。 二、 董事会的责任 按照中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、上海证券交易所《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》编制《2024 年度募集资金存放与使用情况的 专项报告》》是皓元医药董事会的责任，这种责任包括保证其内容真实、准确、完 整，不存在虚假记录、误导性陈述或重大遗漏。 四、 工作概述 我们按照《中国注册会计师其他鉴证业务准则第 ...

Core Viewpoint - The company and its subsidiaries plan to apply for a total comprehensive credit limit of up to 1.21 billion yuan from banks for the year 2025, with the company providing guarantees for these credit facilities [1][2][9]. Group 1: Credit Application Details - The total proposed credit limit is 121 million yuan, which will be used for normal operations and development needs [1][2]. - Specific banks involved in the credit application include Bank of China, Everbright Bank, China Merchants Bank, and others, with various amounts allocated to different subsidiaries [1][3]. - The credit application includes amounts such as 80 million yuan for the company itself and 41 million yuan for its subsidiaries [1][3]. Group 2: Guarantee Provision - The company intends to provide guarantees totaling no more than 20 million yuan for its subsidiaries [2][9]. - The current balance of guarantees provided by the company to its subsidiaries is 10 million yuan for Hefei Ouchuang and 1 million yuan for both Yantai Haoyuan and Yaoyuan Pharmaceutical [2][9]. - The company has no overdue guarantees or guarantees related to litigation [2][9]. Group 3: Internal Decision-Making Process - The board of directors and the supervisory board approved the credit application and guarantee provision on March 26, 2025, without needing to submit the matter to the shareholders' meeting [4][12]. - The decision was made considering the operational needs and overall development strategy of the company and its subsidiaries [10][12]. Group 4: Financial Performance - As of December 31, 2024, the total assets of the company were approximately 111 million yuan, with total liabilities of about 40.9 million yuan, resulting in a net asset value of around 70.2 million yuan [5][7]. - The company reported a revenue of approximately 105.6 million yuan and a net profit of about 35 million yuan for the year 2024 [5][7]. Group 5: Risk Management - The company maintains control over its subsidiaries, which are either wholly owned or controlled, ensuring manageable risk levels associated with the guarantees [10][12]. - The company believes that the guarantee provision will not adversely affect the interests of the company and its shareholders [10][12].

Core Viewpoint - The company announced a provision for asset impairment totaling 147.68 million yuan for the year 2024, significantly impacting its net profit and reflecting a cautious approach to financial reporting [1][2]. Summary by Sections Asset Impairment Provision Overview - The company recognized an inventory impairment provision of 129.23 million yuan, which will reduce the total profit for 2024 by the same amount, leading to a net profit decrease of 118.20 million yuan, accounting for 58.63% of the audited net profit for the year [1][2]. Specifics of the Impairment Provision - The total asset impairment loss amounted to 147.68 million yuan, which includes: - Credit impairment losses for accounts receivable: 12.82 million yuan - Credit impairment losses for other receivables: 3.51 million yuan - Inventory impairment loss: 129.23 million yuan - Contract asset impairment loss: 2.13 million yuan [1][2]. Impact on Financial Statements - The total provision for asset and credit impairment losses will decrease the company's equity by 132.89 million yuan as of the end of the reporting period [2]. Opinions from the Board and Supervisory Committee - The Board's Audit Committee and the Supervisory Committee both approved the asset impairment provision, affirming that it aligns with the principles of prudence and complies with accounting standards, thereby accurately reflecting the company's financial status [3][4][6].

上海皓元医药股份有限公司 董事会审计委员会对会计师事务所 2024 年度 履行监督职责情况报告 上海皓元医药股份有限公司（以下简称"公司"）聘请容诚会计师事务所 （特殊普通合伙）（以下简称"容诚会计师事务所"）作为公司 2024 年度审计 机构。根据《中华人民共和国公司法》《中华人民共和国证券法》和《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规范性文件 的规定，以及公司《董事会审计委员会实施细则》的有关规定，现将公司董事 会审计委员会对会计师事务所 2024 年度履行监督职责情况报告汇报如下： 一、2024 年年审会计师事务所基本情况 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普 通合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普 通合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从 事证券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢外经贸大厦 （二）审计委员会通过召开现场会议的方式与负责公司审计工作的注册会 计师及项目经理召开沟通会议，对 2024 年度审计工作的初步预审情况，如 ...

Core Viewpoint - The independent directors of Shanghai Haoyuan Pharmaceutical Co., Ltd. have been evaluated for their independence and found to comply with relevant regulations, ensuring they can perform their duties without external influence [1][2]. Group 1 - The board of directors conducted an assessment of the independence of current independent directors Wang Rui, Huang Yong, Li Yuanyuan, and those whose terms will end in January 2025: Gao Yang, Yuan Bin, and Zhang Xingxian [1]. - The evaluation confirmed that the independent directors do not fall under any disqualifying conditions as per the "Management Measures for Independent Directors of Listed Companies" [1][2]. - Independent directors have adhered to the regulations set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange, ensuring they dedicate sufficient time and effort to fulfill their responsibilities [1].

Core Viewpoint - The independent director of Shanghai Haoyuan Pharmaceutical Co., Ltd. has provided a comprehensive report on their duties and responsibilities for the year 2024, highlighting their active participation in board meetings, adherence to legal regulations, and commitment to protecting shareholder interests [1][2][3]. Group 1: Independent Director's Basic Information - The independent director, Zhang Xingxian, has been serving since December 2019 and is a professor at Zhejiang University of Technology, with a background in organic chemistry [2]. - The board consists of 9 members, with 3 independent directors, meeting the legal requirements [1]. Group 2: Attendance and Participation - The independent director attended all 11 board meetings and participated in 1 annual and 3 temporary shareholder meetings during the reporting period [5]. - All proposals presented at the board meetings received approval, with the independent director voting in favor of all [5][6]. Group 3: Communication and Oversight - The independent director conducted site visits and maintained close communication with management to understand the company's operations and market conditions [6]. - The management team provided necessary support and timely updates to facilitate the independent director's duties [6]. Group 4: Key Focus Areas - The independent director reviewed related party transactions, confirming they were conducted at fair market prices and did not harm the company or shareholders' interests [7][8]. - Financial reports were disclosed in compliance with regulations, ensuring accuracy and completeness [8][9]. Group 5: Internal Controls and Compliance - The company has established a robust internal control system, adhering to relevant laws and regulations to mitigate operational risks [9]. - The independent director confirmed the reappointment of the auditing firm, ensuring compliance with legal standards [9][10]. Group 6: Financial Management and Shareholder Returns - The company managed its fundraising in accordance with regulations, ensuring proper use and disclosure of funds [10]. - The profit distribution plan for 2023 included cash dividends totaling approximately 22.56 million yuan and a stock increase of 60.15 million shares [10][11]. Group 7: Compensation and Incentives - The board approved reasonable compensation for directors and senior management, aligning with industry standards [12]. - The company implemented stock incentive plans to attract and retain talent, ensuring compliance with relevant regulations [15]. Group 8: Overall Assessment - The independent director emphasized the company's effective governance and operational compliance, contributing positively to decision-making processes [17][18]. - The transition to new independent directors was managed smoothly to maintain governance continuity [18].

的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为上海 皓元医药股份有限公司（以下简称"公司"或"皓元医药"）向不特定对象发行 可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证 券交易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律法规和规范性文件的要求，民生证券对皓元医药向 不特定对象发行可转换公司债券部分募投项目延期的事项进行了核查，发表如下 核查意见： 民生证券股份有限公司 关于上海皓元医药股份有限公司 向不特定对象发行可转换公司债券部分募投项目延期 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可20241289 号）同意，公司向不 特定对象发行 82,235.00 万元的可转换公司债券，期限 6 年，每张面值为人民币 100 元，发行数量为 822,350 手（8,223,500 张）。本次发行的募集资金总额为人民币 务所（特殊普通合伙）于 202 ...

证券代码：688131 证券简称：皓元医药 公告编号：2025-034 转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司 第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 与会监事以记名投票表决方式逐项审议并通过了如下议案： （一）审议并通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：3 名赞成，占全体监事人数的 100%；0 名弃权，0 名反对。本议 案尚需提交公司 2024 年年度股东大会审议。 （二）审议并通过《关于公司 2024 年年度报告及摘要的议案》 经审议，监事会认为：董事会编制和审核公司 2024 年年度报告及其摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 名赞成，占全体监事人数的 100%；0 名弃权，0 名反对。本议 案尚需提交公司 2024 年年度股东大会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.c ...